

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Victor J. Dzau, et al. Docket No.: 39753-0021C3  
Serial No.: 09/875,305 Group Art Unit: 1636  
Filing Date: June 5, 2001 Examiner: Marvich, Maria  
For: THERAPEUTIC USE OF CIS-ELEMENT DECOYS IN VIVO

**SUPPLEMENTAL INFORMATION DISCLOSURE**  
**STATEMENT UNDER 37 C.F.R. §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage  
-- OR --

**CERTIFICATE OF MAILING (37 CFR 1.10(a))**

CERTIFICATE OF MAILING BY "EXPRESS MAIL" - Rule 10: I hereby certify that this correspondence is being deposited on August 11, 2003 with the U.S. Postal Service "Express Mail Post Office to Addressee" under 37 CFR 1.10 as **Express Mail No. EV346725809US** addressed to: Mail Stop: RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: August 11, 2003

  
Cheryl Ann Rogers

- ☐ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --
- ☒ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; **or**
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is authorized to charge any required fees, additional fees, or credit any overpayment to Deposit Account 08-1641 (Docket No. 39753-0021C3).

Respectfully submitted,

Dated: August 11, 2003

By: \_\_\_\_\_

Ginger R. Dreger  
Reg. No. 33,055

**HELLER EHRMAN WHITE & MCAULIFFE LLP**  
**Customer No. 25213**  
275 Middlefield Road  
Menlo Park, CA 94025-3506  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

PTO-1449

ATTY. DOCKET NO.:

39753-0021C3

SERIAL NO.:

09/875,305

APPLICANT : Victor J. Dzau, et al.

FILING DATE: 6/5/01

GROUP: 1636

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>


**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Abeyama, K., et al., "A Role for NF-kappaB-dependent Gene Transactivation in Sunburn", J. Clin. Invest 2000 Jun;105(12):1751-9.
	Bishop-Bailey, D., et al., "Endothelial Cell Apoptosis Induced by th Peroxisome Proliferator-activated Receptor (PPAR) Ligand 15-decoy-Delta 12, 14-prostaglandin J2", J. Biol. Chem. 1999 Jun 11;274(24):17042-8.
	Bonham, C.A., et al., "Marked Prolongation of Cardiac Allograft Survival by Dendritic Cells Genetically Engineered with NF-kappa B Oligodeoxyribonucleotide Decoys and Adenoviral Vectors Encoding CTLA4-Ig", J. Immunol 2002 Sep 15;169(6):3382-91.
	Borgatti, M., et al., "Cationic Liposomes as Delivery Systems for Double-stranded PNA-DNA Chimeras Exhibiting Decoy Activity Against NF-kappaB Transcription Factors", Biochem Pharmacol 2002 Aug 15;64(4):609-16.
	Breuer-McHam, J., et al., "Activation of HIV in Human Skin by Ultraviolet B Radiation and its Inhibition by NFkappaB Blocking Agents", Photochem Photobiol 2001 Dec;74(6):805-10.
	Cho-Chung, Y.S., et al., "Oligonucleotides as Transcription Factor Decoys", Curr. Opin. Mol. Ther. 1999 Jun;1(3):386-92.

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>		<b>ATTY. DOCKET NO.:</b> 39753-0021C3	<b>SERIAL NO.:</b> 09/875,305
		<b>APPLICANT : Victor J. Dzau, et al.</b>	
		<b>FILING DATE: 6/5/01</b>	<b>GROUP: 1636</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	Cooper, J.A., Jr., et al., "Attenuation of Interleukin-8 Production by Inhibiting Nuclear Factor-kappaB Translocation Using Decoy Oligonucleotides", Biochem. Pharmacol. 2000 Mar 15;59(6):605-13.		
	D'Acquisto, F., et al., "Local Administration of Transcription Factor Decoy Oligonucleotides to Nuclear Factor-kappaB Prevents Carrageenin-induced Inflammation in Rat Hind Paw", Gene Ther. 2000 Oct;7(20):1731-7.		
	D'Acquisto, F., et al., "Transcription Factor Decoy Oligodeoxynucleotides to Nuclear Factor-kappaB Inhibit Reverse Passive Arthus Reaction in Rat", Naunyn Schmiedebergs Arch. Pharmacol 2001 Nov;364(5):422-9.		
	Feeley, B.T., et al., "Nuclear Factor-kappaB Transcription Factor Decoy Treatment Inhibits Graft Coronary Artery Disease After Cardiac Transplantation in Rodents", Transplantation 2000 Dec 15;70(11):1560-8.		
	Franco, A.V., et al., "The Role of NF-kappa B in TNF-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis on Melanoma Cells", J. Immuno. 2001 May 1;166(9):5337-45.		
	Giannoukakis, N., et al., "Prolongation of Cardiac Allograft Survival Using Dendritic Cells Treated with NF-kB Decoy Oligodeoxyribonucleotides", Mol. Ther. 2000 May;1(5):430-437 (part 1 of 2 parts).		
	Griesenback, U., et al., "Anti-inflammatory Gene Therapy Directed at the Airway Epithelium", Gene Ther. 200 Feb;7(4):306-13.		
	Hess, D.C., et al., "Hypertonic Mannitol Loading of NF-kappaB Transcription Factor Decoys in Human Brain Microvascular Endothelial Cells Blocks Upregulation of ICAM-1", Stroke 2000 May;31(5):1179-86.		
	Kawauchi, M., et al., "Gene Therapy for Attenuating Cardiac Allograft Arteriopathy Using Ex-Vivo E2F Decoy Transfection by HVJ-AVE-liposome Method in Mice and Nonhuman Primates", Circ. Res. 2000 Nov 24;87(11):1063-8.		
	Khaled, A.R., et al., "Use of Phosphorothioate-modified Oligodeoxynucleotides to Inhibit NF-kappaB Expression and Lymphocyte Function", Clin. Immunol. Immunopathol. 1998 Feb; 86(2):170-9.		
	Kitamoto, S., et al., "Increased Activity of Nuclear Factor-kappaB Participates in Cardiovascular Remodeling Induced by Chronic Inhibition of Nitric Oxide Synthesis in Rats", Circulation 2000 Aug 15;102(7):806-12.		
	Kupatt, C., et al., "Retiroinfusion of NfkappaB Decoy Oligonucleotide Extends Cardioprotection Achieved by CD18 Inhibition in a Preclinical Study of Myocardial Ischemia and Retiroinfusion in Pigs", Gene Ther. 2002 Apr;9(8):518-26.		
	Kupatt, C., et al., "Tumor Necrosis Factor-alpha Contributes to Ischemia- and Reperfusion-induced Endothelial Activation in Isolated Hearts", Circ. Res. 1999 Mar 5;84(4):392-400.		
	Li, Y., et al., S100beta Induction of the Proinflammatory Cytokine Interleukin-6 in Neurons", J. Neurochem 2000 Jan;74(1):143-50.		
	Matsushita, H., et al., "Hypoxia-induced Endothelial Apoptosis Through Nuclear Factor-kappaB (NF-kappaB)-mediated bcl-2 Suppression: In Vivo Evidence of the Importance of NF-kappaB in Endothelial Cell Regulation", Circ. Res. 2000 May 12;86(9):974-81.		
	Morishita, R., et al., "In Vivo Transfection of CIS Element "decoy" Against Nuclear Factor-kappaB Binding Site Prevents Myocardial Infarction", Nat Med. 1997 Aug;3(8):894-9.		
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>		<b>ATTY. DOCKET NO.:</b> 39753-0021C3	<b>SERIAL NO.:</b> 09/875,305
			<b>APPLICANT :</b> Victor J. Dzau, et al.	
			<b>FILING DATE:</b> 6/5/01	<b>GROUP:</b> 1636
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>				
	Nakamura, H., et al., "Prevention and Regression of Atopic Dermatitis by Ointment Containing NF-kB Decoy Oligodeoxynucleotides in NC/Nga Atopic Mouse Model", Gene Ther. 2002 Sep;9(18):1221-9. ✓			
	Nishio, E., et al., "The Potentiation of Ox-LDL Induced Apoptosis by Inhibition of NF-kappaB", Life Sci. 2000 Sep8;67(16):1983-92. ✓			
	Ono, S., et al., "Decoy Administration of NF-kappaB into the Subarachnoid Space for Cerebral Angiopathy", Hum. Gene Ther. 1998 May 1;9(7):1003-11. ✓			
	Quan, N., et al., "Administration of NF-kappaB Decoy Inhibits Pancreatic Activation of NF-kappaB and Prevents Diabetogenesis by Alloxan in Mice", FASEB J. 2001 Jul;15(9):1616-8. ✓			
	Romano, M.F., et al., "Enhancement of Cytosine Arabinoside-induced Apoptosis in Human Myeloblastic Leukemia Cells by NF-kappa B/Rel-specific Decoy Oligodeoxynucleotides", Gene Ther. 2000 Jul;7(14):1234-7. ✓			
	Sakaue, G., et al., "NF-kappa B Deoy Suppresses Cytokine Expression and Thermal Hyperalgesia in a Rat Neuropathic Pain Model", Neuroreport 2001 Jul 20; 12(10):2079-84. ✓			
	Sawa, Y., et al., "A Novel Strategy for Myocardial Protection Using in Vivo transfection of CIS Element 'Decoy' Against NfkappaB Binding Site: Evidence for a Role of NfkappaB in Ischemia-reperfusion Injury", Circulation 1997 Nov 4;96(9 Suppl):II-280-4; discussion II-285. ✓			
	Sharma, H.W., et al., "The NF-kappaB Transcription Factor in Oncogenesis", Anticancer Res. 1996 Mar-Apr;16(2):589-96. ✓			
	Shibuya T., et al., "A Double-strand Decoy DNA Oligomer for NF-kappaB Inhibits TNFalpha-induced ICAM-1 Expression in Sinusoidal Endothelial Cells", Biochem. Biophys. Res. Commun. 2002, Oct 18;298(1): 10-16. ✓			
	Shintani T., et al., "Intraoperative Transfection of Vein Grafts with the NfkappaB Decoy in a Canine Aortocoronary Bypass Model: A Strategy to Attenuate Intimal Hyperplasia", Ann Thorac. Surg. 2002, Oct;74(4):1132-7, discussion 1137-8. ✓			
	Sumitomo, M., et al., "An Essential Role for Nuclear Factor KappaB in Preventing TNF-alpha-induced Cell Death in Prostrate Cancer Cells", J. Urol. 1999 Feb;161(2):674-9. ✓			
	Suzuki, J., et al., "Decoy Against Nuclear Factor-kappa B Attenuates Myocardial Cell Infiltration and Arterial Neointimal Formation in Murine Cardiac Allografts", Gene Ther. 2000 Nov;7(21):1847-52. ✓			
	Takeuchi T., et al., "Nuclear Factor-kappaB and TNF-alpha Mediate Gastric Ulceration Induced by Phorbol Myristate Acetate", Dig. Dis. Sci. 2002 Sep;47(9):2070-8. ✓			
	Tomita, N., et al., "In Vivo Administration of a Nuclear Transcription Factor-kappaB Decoy Suppresses Experimental Crescentic Glomerulonephritis", J. AM. Soc. Nephrol 200 Jul;11(7):1244-52. ✓			
	Tomita, N., et al., "Transcription Factor Decoy for NfkappaB Inhibits TNF-alpha-induced Cytokine and Adhesion Molecule Expression in Vivo", Gene Ther. 2000 Aug;7(15):1326-32. ✓			
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE  
STATEMENT**
**PTO-1449**
**ATTY. DOCKET NO.:**
**39753-0021C3**
**SERIAL NO.:**
**09/875,305**
**APPLICANT : Victor J. Dzau, et al.**
**FILING DATE: 6/5/01**
**GROUP: 1636**
**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Tomita, T., et al., "Transcription Factor Decoy for NFkappaB Inhibits Cytokine and Adhesion Molecule Expressions in Synovial Cells Derived From Rheumatoid Arthritis", Rheumatology (Oxford), 2000 Jul;39(7):749-57. ✓

Tomita, N., et al., "Transcription Factor Decoy for Nuclear Factor-kappaB Inhibits Tumor Necrosis Factor-alpha-induced Expression of Interleukin-6 and Intracellular Adhesion Molecule-1 in Endothelial Cells", J. Hypertens 1998 Jul;16(7):993-1000. ✓

Ueno, T., et al., "Nuclear Factor-kappa B Decoy Attenuates Neuronal Damage After Global Brain Ischemia: A Future Strategy for Brain Protection During Circulatory Arrest", J. Thorac Cardiovasc. Surg. 2001 Oct;122(4):720-7. ✓

Vos, I.H., et al., "NfkappaB Decoy Oligodeoxynucleotides Reduce Monocyte Infiltration in Renal Allografts", FASEB J. 2000 Apr;14(5):815-22. ✓

Yokoseki, O., et al., "CIS Element Decoy Against Nuclear Factor-kappaB Attenuates Development of Experimental Autoimmune Myocarditis in Rats", Circ. Res. 2001 Nov 9;89(10):899-906. ✓

Yoshimura, S., et al., "Inhibition of Intimal Hyperplasia After Balloon Injury in Rat Carotid Artery Model Using CIS-element 'Decoy' of Nuclear Factor-kappaB Binding Site as a Novel Molecular Strategy", Gene Ther. 2001 Nov;8(21):1635-42. ✓

**EXAMINER**
**DATE CONSIDERED**

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.